{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:00:46Z","timestamp":1792522846730,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["209553\/Z\/17\/Z"],"award-info":[{"award-number":["209553\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["227835\/Z\/23\/Z"],"award-info":[{"award-number":["227835\/Z\/23\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.chest.2025.07.4077","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:23:09Z","timestamp":1755235389000},"page":"139-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mortality Outcomes and Angiotensin-Converting Enzyme Inhibitor Use in Patients With Idiopathic Pulmonary Fibrosis"],"prefix":"10.1016","volume":"169","author":[{"given":"Burcu","family":"Ozaltin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0093-1086","authenticated-orcid":false,"given":"Robert","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Follet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vermant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Qummer","family":"Ul Arfeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Fitzpatick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Direk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2025.07.4077_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.chest.2025.07.4077_bib2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12325-018-0693-1","article-title":"Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK","volume":"35","author":"Strongman","year":"2018","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.chest.2025.07.4077_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1378\/chest.10-2572","article-title":"Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium","volume":"140","author":"Nathan","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.chest.2025.07.4077_bib4","article-title":"Mortality and respiratory-related hospitalizations in idiopathic pulmonary fibrosis not treated with antifibrotics","volume":"8","author":"Cottin","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.chest.2025.07.4077_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-022-02033-6","article-title":"Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study","volume":"23","author":"Jovanovic","year":"2022","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.chest.2025.07.4077_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151425","article-title":"Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis","volume":"11","author":"Kreuter","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.chest.2025.07.4077_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12890-023-02340-8","article-title":"Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study","volume":"23","author":"Lee","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.chest.2025.07.4077_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12931-024-02875-2","article-title":"Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study","volume":"25","author":"Ozaltin","year":"2024","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.chest.2025.07.4077_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1183\/09031936.00102107","article-title":"Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic study","volume":"31","author":"Papadopoulos","year":"2008","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.chest.2025.07.4077_bib10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.rmed.2010.02.008","article-title":"Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis","volume":"104","author":"Nathan","year":"2010","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2025.07.4077_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3111\/13696998.2012.680553","article-title":"Burden of illness in idiopathic pulmonary fibrosis","volume":"15","author":"Collard","year":"2012","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.chest.2025.07.4077_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02279-2019","article-title":"Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry","volume":"56","author":"Behr","year":"2020","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2025.07.4077_bib13","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","volume":"2008","author":"Heran","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.chest.2025.07.4077_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.chest.2025.07.4077_bib15","doi-asserted-by":"crossref","first-page":"33677","DOI":"10.1038\/srep33677","article-title":"Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure","volume":"6","author":"Wei","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.chest.2025.07.4077_bib16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/hrt.2004.035618","article-title":"Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice","volume":"91","author":"Yoshiyama","year":"2005","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.chest.2025.07.4077_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/HYPERTENSIONAHA.120.16352","article-title":"Transient ACE (angiotensin-converting enzyme) inhibition suppresses future fibrogenic capacity and heterogeneity of cardiac fibroblast subpopulations","volume":"77","author":"Garvin","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.chest.2025.07.4077_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI46215","article-title":"Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice","volume":"122","author":"Podowski","year":"2012","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.chest.2025.07.4077_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/1319-3767.195559","article-title":"Effect of angiotensin-converting enzyme inhibitor, lisinopril on morphological and biochemical aspects of fibrotic liver regeneration","volume":"22","author":"Ambreen","year":"2016","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.chest.2025.07.4077_bib20","doi-asserted-by":"crossref","first-page":"109770","DOI":"10.1016\/j.abb.2023.109770","article-title":"Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells","volume":"748","author":"Huang","year":"2023","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"10.1016\/j.chest.2025.07.4077_bib21","first-page":"827","article-title":"Data resource profile","volume":"44","author":"Herrett","year":"2015","journal-title":"Clinical Practice Research Datalink (CPRD), Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.chest.2025.07.4077_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.chest.2019.04.015","article-title":"Association of angiotensin modulators with the course of idiopathic pulmonary fibrosis","volume":"156","author":"Kreuter","year":"2019","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2025.07.4077_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/resp.12781","article-title":"Cardiovascular and antacid treatment and mortality in oxygen-dependent pulmonary fibrosis: a population-based longitudinal study","volume":"21","author":"Ekstr\u00f6m","year":"2016","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.chest.2025.07.4077_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0012-3692(15)31155-7","article-title":"Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis","volume":"126","author":"Nadrous","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.chest.2025.07.4077_bib25","doi-asserted-by":"crossref","first-page":"771804","DOI":"10.3389\/fphar.2021.771804","article-title":"The effect of cardiovascular medications on disease-related outcomes in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","author":"Zhang","year":"2021","journal-title":"Front Pharmacol. 12"},{"issue":"5","key":"10.1016\/j.chest.2025.07.4077_bib26","doi-asserted-by":"crossref","first-page":"L887","DOI":"10.1152\/ajplung.00432.2005","article-title":"Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis","volume":"291","author":"Li","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.chest.2025.07.4077_bib27","doi-asserted-by":"crossref","first-page":"L178","DOI":"10.1152\/ajplung.00009.2008","article-title":"Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis","volume":"295","author":"Li","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"10.1016\/j.chest.2025.07.4077_bib28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.biocel.2011.11.019","article-title":"Angiotensin signalling in pulmonary fibrosis","volume":"44","author":"Uhal","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"10.1016\/j.chest.2025.07.4077_bib29","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1159\/000430131","article-title":"Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice","volume":"36","author":"Wang","year":"2015","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"10.1016\/j.chest.2025.07.4077_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1183\/09031936.00015808","article-title":"Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression","volume":"32","author":"Molina-Molina","year":"2008","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.chest.2025.07.4077_bib31","doi-asserted-by":"crossref","first-page":"24029","DOI":"10.3390\/ijms141224029","article-title":"Hypoxia-induced collagen synthesis of human lung fibroblasts by activating the angiotensin system","volume":"14","author":"Liu","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.chest.2025.07.4077_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","article-title":"Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases","volume":"40","author":"Tan","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.chest.2025.07.4077_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fcvm.2020.00115","article-title":"Angiotensin converting enzyme inhibitors (ACEIs) decrease the progression of cardiac fibrosis in rheumatic heart disease through the inhibition of IL-33\/sST2","volume":"7","author":"Ambari","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.chest.2025.07.4077_bib34","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2174\/138161207780618885","article-title":"Angiotensin-TGF-beta1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages","volume":"13","author":"Uhal","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.chest.2025.07.4077_bib35","doi-asserted-by":"crossref","first-page":"40523","DOI":"10.1038\/srep40523","article-title":"Pirfenidone controls the feedback loop of the AT1R\/p38 MAPK\/renin-angiotensin system axis by regulating liver X receptor-\u03b1 in myocardial infarction-induced cardiac fibrosis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369225050196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369225050196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:29:57Z","timestamp":1778646597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369225050196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0012369225050196"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2025.07.4077","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality Outcomes and Angiotensin-Converting Enzyme Inhibitor Use in Patients With Idiopathic Pulmonary Fibrosis","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.07.4077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}